Ranbaxy Laboratories Ltd. et al.

Ranbaxy Laboratories Ltd. ("Ranbaxy") was an Indian multinational generic pharmaceutical company, incorporated in 1961 (its founders began as a Shionogi distributor in 1937) and headquartered in Gurgaon, Haryana, India. It listed on Indian exchanges in 1973. In 2008 Japan's Daiichi Sankyo acquired a majority stake (~63.9%) for roughly $4.6 billion, and in 2014–15 Sun Pharmaceutical Industries acquired Ranbaxy in an all-stock deal valued at about $4 billion. Ranbaxy was delisted in April 2015 and ceased to exist as a standalone entity, its branded business absorbed into Sun Pharma. Reported headcount was around 11,000 (2012) and global sales about US$1.5 billion in 2009.

Products / operations. Ranbaxy manufactured and marketed generic and branded-generic prescription drugs, over-the-counter products (e.g., Volini, Revital) and active pharmaceutical ingredients, with sales in more than 100 countries and manufacturing sites in India (Paonta Sahib, Dewas, Toansa, Mohali) plus facilities in the US and Romania. It pursued first-to-file generic opportunities in the US, including valacyclovir, sumatriptan and oxcarbazepine. The company's later years were dominated by FDA import alerts and a 2013 US guilty plea and $500 million DOJ settlement over manufacturing and data-integrity violations.

Litigation posture. Ranbaxy appears in the tracked data as a pure defendant (0 plaintiff, 1 defendant case), consistent with an operating generic manufacturer responding to Hatch-Waxman patent suits rather than a non-practicing entity asserting patents. The single tracked matter, Jazz Pharmaceuticals, Inc. v. Ranbaxy Laboratories Ltd. et al., was filed in the District of New Jersey — a common venue for ANDA litigation because many generic filers, including Ranbaxy's US affiliate, are New Jersey-based.

Notable case context. That suit concerned Ranbaxy's ANDA No. 203351 for 500 mg/mL sodium oxybate oral solution (a proposed generic of Jazz's Xyrem), filed with a Paragraph IV certification against U.S. Patent No. 8,859,619, and sought relief under 35 U.S.C. § 271(e)(2). Jazz ultimately settled with Ranbaxy and other ANDA filers; those settlements were later challenged as allegedly anticompetitive in the consolidated Xyrem antitrust litigation (MDL No. 2966), in which Ranbaxy is named as a defendant. Ranbaxy's involvement in the U.S. Xyrem litigation is now largely inherited by Sun Pharma.